UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of December 2021
Commission File Number: 001-37353
BIONDVAX PHARMACEUTICALS LTD.
(Translation of registrant’s name into English)
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jeusalem, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
On December 27, 2021, BiondVax Pharmaceuticals Ltd. (the “Company”) issued a press release announcing that all proposed resolutions, including the election of the former CFO of GSK’s Global Vaccines Business, Mr. Jay Green, to the Company’s Board of Directors, were approved at the Company’s Annual General Meeting of Shareholders. A copy of the press release is filed herewith as Exhibit 99.1.
On December 29, 2021, the Company issued a press release announcing the successful closing of its $9.8 million follow-on underwritten Offering of ADSs, including exercise of the underwriter’s over-allotment option. A copy of the press release is filed herewith as Exhibit 99.2.
Exhibit Index
Exhibit No. | Description | |
99.1 | Press release, dated December 27, 2021. | |
99.2 | Press release, dated December 29, 2021. |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BiondVax Pharmaceuticals Ltd. | ||
Date: December 30, 2021 | By: | /s/ Amir Reichman |
Amir Reichman | ||
Chief Executive Officer |
2